Abstract
Lung cancer is a major health issue. With 1,8 million new cases every year, it is the leading cause of death by cancer worldwide. In this work, we focused on non small cell lung adenocarcinoma because, from a therapeutic point of view, they are the only histological subtype with targetable molecular alterations. A number of mutations or rearrangements are screened routinely in patients diagnosed with locally advanced unresectable or metastatic lung adenocarcinoma: EGFR (Epidermial Growth Factor Receptor), ALK (Anaplastic Lymphoma Kinase), ROS1 (ROS1 pro-to-oncogene receptor tyrosine kinase), KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), B Raf and HER2 (human epidermal growth factor receptor 2). If one of these alterations is found, patients will in most cases be eligible for a targeted therapy by a tyrosine kinase inhibitor whose efficacy has been proven to be superior to classic chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
